A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.
about
New molecularly targeted therapies for lung cancerVascular endothelial growth factor -2578C/A polymorphism and colorectal cancer risk: A meta-analysisLoss of heterozygosity on chromosome 6q correlates with decreased thrombospondin-2 expression in human salivary gland carcinomasEffects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer.Theranostic tumor homing nanocarriers for the treatment of lung cancerPhase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapyRecombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells.Low density lipoprotein receptor mediates anti-VEGF effect of lymphocyte T-derived microparticles in Lewis lung carcinoma cellsVEGF blocking therapy in the treatment of cancer.Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.Molecular pathology of non-small-cell lung cancer.Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non-small-cell Lung CancerEpidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.Therapeutic options to target angiogenesis in human malignancies.Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.Bevacizumab for the treatment of advanced non-small-cell lung cancer.Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosisHost deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo.Angiogenesis in the treatment of non-small cell lung cancer.Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancerEvolving strategies: future treatment of glioblastoma.Novel strategies for the treatment of small-cell lung carcinoma.Targeting VEGF in lung cancer.The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.Antibodies as stratagems against cancer.The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer.The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis.Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1beta and hypoxia in small cell lung cancer.Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas.Antiangiogenic therapies: is VEGF-A inhibition alone enough?Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.Combined treatment targeting HIF-1α and Stat3 is a potent strategy for prostate cancer therapy.Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors.
P2860
Q24680988-0540081E-0B6E-4F18-BCD4-2AC69B6DBFA5Q26776249-9217510B-74EB-4ED8-9541-8B63F4B023C1Q28181944-5C534535-0484-4B7F-9E6C-42DBD47525F3Q33356757-963222F9-220C-4E20-A509-B01724A66753Q33401434-3816B9FB-06C5-435F-8D7E-02C91FEF9BBFQ33425221-D23F862D-B480-43EF-8B50-10B1A08CEBF6Q33429478-11ED0E32-86B7-40BE-B70D-39D240B567A8Q33576258-06220942-812E-42DA-A245-606C5CB10B65Q33769951-B78944A6-7017-46FA-9758-5094A3BAE38FQ34026037-2BA6B46A-27A7-4273-959E-DA69268B4375Q34310069-5A32EB4A-EBCE-4C98-84B2-4B04B4FEC937Q34362205-59C8F0FD-41BD-44D3-B7F8-C0F4B303833BQ34582188-91F577E8-1F46-41A4-83CF-5C08B6EE6010Q35093616-48A7467E-844A-4DA5-A81D-4876F7B97E70Q36084854-4B1D28D7-DEBE-4F5F-9C99-27D9C16EBE7AQ36155104-E9EF689F-E826-4A67-BCEC-F7630554827BQ36192506-3004B3BD-DBAB-4DEC-8C7D-13BBAC7702F5Q36482542-C40B4137-F76C-4B3A-8452-8018E0BD6AA2Q36634261-F6AB6DC9-757E-4D08-A898-C8E4749DEE55Q36691776-89C88868-EF9E-40AD-A37A-899EBB588172Q37159495-C3FD119C-9584-4428-AE19-9FF4317D5D2AQ37250349-6B6DDD07-7EC3-4BB9-9AC9-1D475D470559Q37337431-090CECF3-8024-48C5-9990-8923F1743812Q37435385-3AE2E925-32EF-48A3-91C0-0695CBA0E70AQ37486262-E474F107-F3A7-4435-94C8-87D8AB9E823CQ37862235-9767004E-3E1F-4723-8F65-EC60240BBD41Q37892341-2D709A21-0C20-4888-96DA-124006948AB6Q37996080-F033891D-C980-4106-A634-7E170C01CF42Q38536377-B337363C-669E-4C73-AB54-C0F5B26D5B91Q38688747-D9095FCC-9B8A-4DE9-BE23-95840C21795AQ39815570-2CFD9AA3-0491-4BBE-BDB6-718510FA258FQ40041786-52B79EE1-8792-42E7-808E-120C6D1ACCEBQ40276112-49C554E9-29C2-4426-B6C2-29B74446124DQ45253538-3154D5BB-93EE-4075-B3B8-CE3A3BFAF330Q45820306-30A0C440-51B1-4A76-B12F-4D76487E932BQ46948139-459B7156-A7A0-45DF-AA95-4FD6DCE54BCCQ53255017-A7D7AB42-1C45-4552-9BE5-ADBC02552DDCQ53335025-4FF270FE-502E-40A3-8629-C692D1512CC1
P2860
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
A high vascular count and over ...... ted small cell lung carcinoma.
@ast
A high vascular count and over ...... ted small cell lung carcinoma.
@en
type
label
A high vascular count and over ...... ted small cell lung carcinoma.
@ast
A high vascular count and over ...... ted small cell lung carcinoma.
@en
prefLabel
A high vascular count and over ...... ted small cell lung carcinoma.
@ast
A high vascular count and over ...... ted small cell lung carcinoma.
@en
P2093
P2860
P50
P356
P1476
A high vascular count and over ...... ated small cell lung carcinoma
@en
P2093
C A Angeletti
M A Mariani
R Pingitore
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600130
P407
P577
2002-02-01T00:00:00Z